{"schema_version":"secwatch.filing_event.v1","accession":"0001129928-26-000043","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-07-13T13:03:54+00:00","discovered_at":"2026-07-13T13:05:00.255054+00:00","generated_at":"2026-07-13T13:05:06.254537+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oncolytics: FDA Type D meeting in Aug; half of REO 033 sites activated, >20 patients pre-identified","bullets":["Company to hold Type D meeting with FDA in first half of August 2026 to discuss registrational design for REO 033 Part B.","Approximately half of planned clinical sites for REO 033 Part A activated by end of July; more than 20 patients pre-identified.","Initial tumor response update from Part A expected by year-end 2026; Part B enrollment could begin Q1 2027 subject to FDA feedback.","Pelareorep has Fast Track designation from FDA for RAS-mutant MSS metastatic colorectal cancer.","Global lead PI Dr. Sanjay Goel opened enrollment at Rutgers Cancer Institute; remaining sites to be activated by end of August."],"urls":{"canonical":"https://secwatch.observer/filing/0001129928-26-000043","json":"https://secwatch.observer/filing/0001129928-26-000043.json","markdown":"https://secwatch.observer/filing/0001129928-26-000043.md","text":"https://secwatch.observer/filing/0001129928-26-000043.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000043/0001129928-26-000043-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000112992826000043/oncy-20260713.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T13:05:06.254537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}